Novartis AG or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?

Managing SG&A Costs: Novartis AG vs. CRISPR Therapeutics AG

In the competitive world of biotechnology and pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Novartis AG and CRISPR Therapeutics AG have demonstrated contrasting approaches to handling these costs.

From 2014 to 2023, Novartis AG consistently reported SG&A expenses averaging around $14.5 billion annually, reflecting its expansive global operations. Despite a slight decrease in 2023, Novartis's SG&A costs remained relatively stable, showcasing its ability to manage large-scale operations efficiently.

Conversely, CRISPR Therapeutics AG, a smaller entity, saw its SG&A expenses grow from approximately $5 million in 2014 to over $76 million in 2023. This increase, while significant, aligns with its rapid growth and expansion in the gene-editing sector.

Ultimately, while Novartis maintains a steady hand on its vast expenses, CRISPR's rising costs highlight its aggressive growth strategy in a burgeoning industry.